- Home
- RILY vs MOLN Comparison
RILY vs MOLN Comparison
Compare RILY & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RILY | MOLN |
|---|---|---|
| Founded | 1973 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.3M | 151.2M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RILY | MOLN |
|---|---|---|
| Price | $9.35 | $4.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 2.4M | 4.5K |
| Earning Date | 01-14-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 6.99 | N/A |
| Revenue | ★ $850,342,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $999.99 |
| P/E Ratio | $1.31 | ★ N/A |
| Revenue Growth | ★ 33.29 | N/A |
| 52 Week Low | $2.67 | $3.36 |
| 52 Week High | $10.97 | $5.41 |
Technical Indicators
Market Signals| Indicator | RILY | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 68.05 | 52.16 |
| Support Level | $8.25 | $3.97 |
| Resistance Level | $10.31 | $4.29 |
| Average True Range (ATR) | 1.00 | 0.16 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 69.80 | 53.60 |
Price Performance
Historical ComparisonAbout RILY B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.